8-K: MetaVia Partners Syntekabio for AI Drug Discovery

MetaVia Inc. announced a research collaboration with Syntekabio, Inc. to leverage AI for expanding the therapeutic potential of its novel oral GPR119 agonist, DA-1241, following positive Phase 2a results.

Summary

• MetaVia Inc. (Nasdaq: MTVA) has entered into a research collaboration with Syntekabio, Inc., a leading artificial intelligence (AI)-driven drug discovery company.
• The collaboration aims to identify additional disease targets and optimize the therapeutic profile of DA-1241, MetaVia's novel oral G-Protein-Coupled Receptor 119 (GPR119) agonist.
• This partnership follows positive results from MetaVia's 16-week, 109-subject Phase 2a study of DA-1241.
• The Phase 2a study demonstrated a favorable safety and tolerability profile, alongside both hepatoprotective and glucose-regulating effects in presumed metabolic dysfunction-associated steatohepatitis (MASH) patients.
• Syntekabio's proprietary DeepMatcher compound-protein interaction (CPI) AI prediction platform will be utilized to conduct large-scale virtual screening against more than 1,700 validated protein targets.
• The objective of the screening is to uncover new, high-potential indications for DA-1241 while ensuring specificity and minimizing the risk of off-target effects.
• DA-1241 is being developed with optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes (T2D).
• Agonism of GPR119 by DA-1241 promotes the release of key gut peptides GLP-1, GIP, and PYY, which play roles in glucose metabolism, lipid metabolism, and weight loss.
• Pre-clinical studies of DA-1241 showed beneficial effects on glucose, lipid profile, and liver inflammation, reducing hepatic steatosis, inflammation, and fibrosis, and improving glucose control.
• DA-1241 was well tolerated in Phase 1a, 1b, and 2a trials in both healthy volunteers and those with T2DM, and demonstrated direct hepatic action in the Phase 2a study.
• MetaVia is also developing DA-1726 for the treatment of obesity, which is a novel oxyntomodulin (OXM) analogue functioning as a GLP1R and GCGR dual agonist, showing best-in-class potential for weight loss, glucose control, and waist reduction in a Phase 1 multiple ascending dose (MAD) trial.

Sentiment

Score: 8

Explanation: The filing announces a strategic collaboration leveraging AI for drug discovery, following positive Phase 2a clinical trial results for DA-1241. This indicates strong progress and potential expansion of the drug's applications, which is a significant positive for the company's pipeline and future value. While standard biotech risks are noted, no immediate negative financial or operational issues are disclosed.

Positives

• Positive results from the 16-week, 109-subject Phase 2a study of DA-1241, demonstrating a favorable safety and tolerability profile.
• DA-1241 showed both hepatoprotective and glucose-regulating effects in presumed MASH patients.
• Strategic research collaboration with Syntekabio, Inc. leverages advanced AI (DeepMatcher platform) to expand DA-1241's therapeutic potential.
• The AI platform will conduct large-scale virtual screening against over 1,700 protein targets, aiming to accelerate discovery and maximize DA-1241's value.
• The data-driven approach seeks to uncover new, high-potential indications while ensuring specificity and minimizing off-target effects.
• DA-1241 is described as a 'unique oral, well-tolerated candidate' with the potential to address a range of unmet medical needs.
• Initial insights from the collaboration are anticipated later this year.

Risks

• Ability to execute on commercial strategy.
• Sufficiency of existing cash on hand to fund operations.
• Timeline for regulatory submissions.
• Ability to obtain regulatory approval through the development steps of current and future product candidates.
• Ability to realize the benefits of the license agreement with Dong-A ST Co. Ltd., including the impact on future financial and operating results.
• Cooperation of contract manufacturers, clinical study partners, and others involved in the development of current and future product candidates.
• Potential negative interactions between product candidates and any other products with which they are combined for treatment.
• Ability to initiate and complete clinical trials on a timely basis.
• Ability to recruit subjects for clinical trials.
• Whether results from clinical trials are consistent with the results of pre-clinical and previous clinical trials.
• Impact of costs related to the license agreement, known and unknown, including costs of any litigation or regulatory actions.
• Effects of changes in applicable laws or regulations.
• Effects of changes to stock price on the terms of the license agreement and any future fundraising.

Future Outlook

MetaVia expects initial insights from the collaboration with Syntekabio later this year. The partnership aims to strategically expand the potential value of DA-1241 by uncovering new, high-potential indications and ensuring specificity, thereby accelerating discovery and maximizing the drug's value.

Management Comments

• "The strong safety and tolerability profile shown in our Phase 2a data gives us confidence in DA-1241s broader therapeutic potential." Hyung Heon Kim, President and Chief Executive Officer of MetaVia.
• "Building on this clinical foundation, we are collaborating with Syntekabio to strategically expand the potential value of DA-1241." Hyung Heon Kim.
• "Specifically, we will leverage their proprietary DeepMatcher compound-protein interaction (CPI) AI prediction platform to conduct large-scale virtual screening against more than 1,700 validated protein targets to uncover new, high-potential indications while ensuring specificity and minimizing the risk of off-target effects." Hyung Heon Kim.
• "This data-driven approach will allow us to accelerate discovery and maximize the value of DA-1241." Hyung Heon Kim.
• "We believe this unique oral, well-tolerated candidate has the potential to address a range of unmet needs, and we look forward to initial insights from the collaboration later this year." Hyung Heon Kim.

Industry Context

This collaboration highlights a growing trend in the biotechnology and pharmaceutical industries: the integration of artificial intelligence (AI) and machine learning (ML) for accelerated drug discovery and development. AI platforms like Syntekabio's DeepMatcher are becoming crucial tools for efficiently screening vast numbers of potential drug targets and compounds, potentially reducing the time and cost associated with traditional drug discovery. This partnership positions MetaVia to leverage cutting-edge technology to expand the utility of its promising drug candidate, DA-1241, in the competitive cardiometabolic disease space, where there is significant unmet need for effective and well-tolerated treatments for conditions like MASH and T2D.

Comparison to Industry Standards

• The use of AI platforms for drug discovery, such as Syntekabio's DeepMatcher, aligns with a growing industry trend seen in partnerships between major pharmaceutical companies and AI biotech firms (e.g., AstraZeneca with BenevolentAI, Sanofi with Exscientia).
• The Phase 2a study of DA-1241 involved 109 subjects over 16 weeks, which is a standard size and duration for early-stage clinical trials in metabolic diseases.
• DA-1241's dual action on glucose and lipid metabolism, along with hepatoprotective effects, positions it in a competitive landscape with other GPR119 agonists and broader cardiometabolic drug candidates, including GLP-1 receptor agonists (e.g., Novo Nordisk's Ozempic/Wegovy, Eli Lilly's Mounjaro/Zepbound) and other MASH treatments in development (e.g., Madrigal Pharmaceuticals' resmetirom).
• MetaVia's DA-1726, an oxyntomodulin analogue, is positioned as a GLP1R and GCGR dual agonist, a mechanism similar to Eli Lilly's tirzepatide (Mounjaro/Zepbound), which has shown significant weight loss and glucose control in clinical trials, setting a high bar for "best-in-class potential."

Stakeholder Impact

• Shareholders: Potential for increased long-term value due to expanded therapeutic potential of DA-1241 and accelerated drug discovery.
• Patients: Potential for new and improved treatment options for cardiometabolic diseases, including MASH and Type 2 Diabetes.
• Employees: Potential for increased research and development activities, possibly leading to growth opportunities.
• Partners (Syntekabio): Validation of their AI platform and potential for future collaborations and revenue streams.

Next Steps

• Syntekabio to conduct large-scale virtual screening against over 1,700 validated protein targets using its DeepMatcher platform.
• Expect initial insights from the collaboration later this year.
• Continued development of DA-1241 for MASH and T2D.
• Continued development of DA-1726 for obesity.

Key Dates

Recommendation

The announcement of a strategic AI-driven collaboration with Syntekabio, following positive Phase 2a results for DA-1241, significantly de-risks the drug's development and expands its market potential. The favorable safety and efficacy profile of DA-1241 in MASH patients, combined with the accelerated discovery of new indications through AI, positions MetaVia for substantial future growth. This partnership enhances the company's pipeline value and competitive edge in the cardiometabolic disease space, making it an attractive investment.

Keywords

MetaVia, Syntekabio, AI drug discovery, DA-1241, GPR119 agonist, MASH, Type 2 Diabetes, Cardiometabolic diseases, Biotechnology, Clinical-stage, DeepMatcher, Drug development, Phase 2a, GLP-1, GIP, PYY, DA-1726, Obesity